All In Biotech

Drug Trial Radar · NCT00443053

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg Subcutaneously) for the Treatment of Patients With Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to Prevent Thromboembolic Complications

Last checked: Nov 20, 2026Latest source record: Mar 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,002 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,002

Actual

Start

Mar 2007

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.

Conditions

  • Thrombosis, Venous

Interventions

  • Fondaparinux 2.5mg or placeboDrug

    Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47Time frame: Baseline to Day 47

Locations

227 sites in 17 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Brno, Czechia

  • GSK Investigational Site

    Olomouc, Czechia

  • GSK Investigational Site

    Pilsen, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Říčany, Czechia

  • GSK Investigational Site

    Tábor, Czechia

  • GSK Investigational Site

    Saku, Estonia

  • GSK Investigational Site

    Tallinn, Estonia

  • GSK Investigational Site

    Tallinn, Estonia

  • GSK Investigational Site

    Tartu, Estonia

  • GSK Investigational Site

    Abbeville, France

  • GSK Investigational Site

    Alès, France

  • GSK Investigational Site

    Amiens, France

  • GSK Investigational Site

    Annecy, France

  • GSK Investigational Site

    Annonay, France

  • GSK Investigational Site

    Arras, France

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Brest, France

  • GSK Investigational Site

    Clermont-Ferrand, France

  • GSK Investigational Site

    Grenoble, France

  • GSK Investigational Site

    Montpellier, France

  • GSK Investigational Site

    Nice, France

  • GSK Investigational Site

    Nîmes, France

  • GSK Investigational Site

    Saint-Aubin-sur-Scie, France

  • GSK Investigational Site

    Saint-Priest-en-Jarez, France

  • GSK Investigational Site

    Tarbes, France

  • GSK Investigational Site

    Toulon, France

  • GSK Investigational Site

    Toulouse, France

  • GSK Investigational Site

    Valenciennes, France

  • GSK Investigational Site

    Villeurbanne, France

  • GSK Investigational Site

    Baesweiler, Baden-Wurttemberg, Germany

  • GSK Investigational Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • GSK Investigational Site

    Heidelberg, Baden-Wurttemberg, Germany

  • GSK Investigational Site

    Karlsbad, Baden-Wurttemberg, Germany

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.